These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18091321)

  • 41. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer.
    Rolland P; Spendlove I; Madjd Z; Rakha EA; Patel P; Ellis IO; Durrant L
    Int J Cancer; 2007 Mar; 120(6):1311-7. PubMed ID: 17187363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemical analysis of P(53) and bcl-2 in benign and malignant salivary glands tumors.
    Al-Rawi NH; Omer H; Al Kawas S
    J Oral Pathol Med; 2010 Jan; 39(1):48-55. PubMed ID: 19761475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma.
    Visscher DW; Sarkar F; Tabaczka P; Crissman J
    Mod Pathol; 1996 Jun; 9(6):642-6. PubMed ID: 8782201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma.
    Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Motoo Y; Okai T; Sawabu N
    Br J Cancer; 1999 Jun; 80(7):1075-9. PubMed ID: 10362119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
    Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
    Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
    Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
    Volm M; Efferth T; Mattern J
    Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
    Vargas MP; Vargas HI; Kleiner DE; Merino MJ
    Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
    Albanell J; Bellmunt J; Molina R; García M; Caragol I; Bermejo B; Ribas A; Carulla J; Gallego OS; Español T; Solé Calvo LA
    Anticancer Res; 1996; 16(2):1027-32. PubMed ID: 8687094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Her-2/neu, p-53, and their coexpression in osteosarcoma.
    Bakhshi S; Gupta A; Sharma MC; Khan SA; Rastogi S
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):245-51. PubMed ID: 19346874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The relationship between p53 protein and c-erb B-2 expression and apoptosis in colorectal cancer].
    He Q; Ohaki Y; Tanaka N; Asano G
    Nihon Ika Daigaku Zasshi; 1999 Jun; 66(3):181-7. PubMed ID: 10401235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of histological and biological markers in pharyngeal squamous cell carcinoma: a case-control study.
    Guerry M; Vabre L; Talbot M; Mamelle G; Leridant AM; Hill C; Bosq J; Luboinski B; Janot F
    Br J Cancer; 1998 Jun; 77(11):1932-6. PubMed ID: 9667670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors.
    Chang K; Ding I; Kern FG; Willingham MC
    J Histochem Cytochem; 1991 Sep; 39(9):1281-7. PubMed ID: 1680897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinico-Pathological and Prognostic Significance of p53, Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray.
    Ismail HM; El-Baradie M; Moneer M; Khorshid O; Touny A
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):3-14. PubMed ID: 18839030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival.
    Dugan MC; Dergham ST; Kucway R; Singh K; Biernat L; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
    Pancreas; 1997 Apr; 14(3):229-36. PubMed ID: 9094152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney.
    Huang SS; Huang JS
    J Biol Chem; 1992 Jun; 267(16):11508-12. PubMed ID: 1350785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.